Impax launches generic Renvela

|About: Impax Laboratories, Inc. (IPXL)|By:, SA News Editor

Impax Laboratories' (IPXL) +1.8%) Global Pharamaeuticals division launches its generic version of Genzyme's (SNY +0.2%) Renvela (sevelamer carbonate).

The company will sell a specific allotment of bottles granted under a license from Genzyme. Impax's aNDA for the product is currently under regulatory review.

The U.S. Renvela market is ~$900M.